Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lachmann

Showing results (311-320 of 426) with videos related to

Pageof 43
Sort By:
Haematologica|July 3, 2025
A retrospective study of isatuximab-pomalidomide-dexamethasone in relapsed/refractory systemic AL amyloidosisSargam Rachit Vohra, Sriram Ravichandran, Darren Foard, et al.
European Heart Journal|January 1, 2015
A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosisRabya H Sayed, Dominic Rogers, Fakhar Khan, et al.
Annals of the Rheumatic Diseases|September 13, 2013
Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromesMaryam Piram, Isabelle Koné-Paut, Helen J Lachmann, et al.
Sleep Medicine|April 4, 2017
High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot studyShameem Mahmood, Milind Sovani, Peter Smith, et al.
Rheumatology (Oxford, England)|December 17, 2020
Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approachSeza Özen, Erdal Sag, Eldad Ben-Chetrit, et al.
British Journal of Haematology|August 15, 2019
A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United KingdomFaye A Sharpley, Aviva Petrie, Shameem Mahmood, et al.
Blood|September 23, 2015
Natural history and outcome of light chain deposition diseaseRabya H Sayed, Ashutosh D Wechalekar, Janet A Gilbertson, et al.
Blood|February 15, 2012
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survivalChristopher P Venner, Thirusha Lane, Darren Foard, et al.
British Journal of Haematology|February 21, 2025
Outcomes of daratumumab-bortezomib-thalidomide-dexamethasone in treatment-naive systemic AL amyloidosisJahanzaib Khwaja, Sriram Ravichandran, Oliver Cohen, et al.
Allergy|September 18, 2012
How not to miss autoinflammatory diseases masquerading as urticariaK Krause, C E Grattan, C Bindslev-Jensen, et al.
Pageof 43

Showing results (311-320 of 426) with videos related to

Sort By:
Pageof 43
Haematologica|July 3, 2025
A retrospective study of isatuximab-pomalidomide-dexamethasone in relapsed/refractory systemic AL amyloidosisSargam Rachit Vohra, Sriram Ravichandran, Darren Foard, et al.
European Heart Journal|January 1, 2015
A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosisRabya H Sayed, Dominic Rogers, Fakhar Khan, et al.
Annals of the Rheumatic Diseases|September 13, 2013
Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromesMaryam Piram, Isabelle Koné-Paut, Helen J Lachmann, et al.
Sleep Medicine|April 4, 2017
High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot studyShameem Mahmood, Milind Sovani, Peter Smith, et al.
Rheumatology (Oxford, England)|December 17, 2020
Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approachSeza Özen, Erdal Sag, Eldad Ben-Chetrit, et al.
British Journal of Haematology|August 15, 2019
A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United KingdomFaye A Sharpley, Aviva Petrie, Shameem Mahmood, et al.
Blood|September 23, 2015
Natural history and outcome of light chain deposition diseaseRabya H Sayed, Ashutosh D Wechalekar, Janet A Gilbertson, et al.
Blood|February 15, 2012
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survivalChristopher P Venner, Thirusha Lane, Darren Foard, et al.
British Journal of Haematology|February 21, 2025
Outcomes of daratumumab-bortezomib-thalidomide-dexamethasone in treatment-naive systemic AL amyloidosisJahanzaib Khwaja, Sriram Ravichandran, Oliver Cohen, et al.
Allergy|September 18, 2012
How not to miss autoinflammatory diseases masquerading as urticariaK Krause, C E Grattan, C Bindslev-Jensen, et al.
Pageof 43